Payment overview · 2025
General Payments
$496.84
9 reported records · 6 companies
Healthcare provider profile · identity verified
Siva K Kumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · TAMPA, FL · NPI 1538267661
Verified facts
What the public records show
CMS Open Payments records show Siva K Kumar, MD received $496.84 in general payments during 2025 across 9 reported records.
Bard Peripheral Vascular, Inc. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Verquvo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $155.27 | 31.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $137.38 | 27.6% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $67.21 | 13.5% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.62 | 13.2% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $38.41 | 7.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.95 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $496.84 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $155.27 | 1 | 2025 |
Source payment records
|
|||||
| Orenitram Normalized: orenitram |
Drug | United Therapeutics Corporation | $67.21 | 2 | 2025 |
Source payment records
|
|||||
| Remodulin Normalized: remodulin |
Drug | United Therapeutics Corporation | $67.21 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $65.62 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $32.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Entresto | Sacubitril/Valsartan | 261 | 70 |
| Farxiga | Dapagliflozin Propanediol | 225 | 60 |
| Carvedilol | Carvedilol | 185 | 52 |
| Spironolactone | Spironolactone | 165 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 126 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 33 |
| Furosemide | Furosemide | 90 | 37 |
| Losartan Potassium | Losartan Potassium | 83 | 27 |
| Potassium Chloride | Potassium Chloride | 83 | 31 |
| Eliquis | Apixaban | 82 | 24 |
| Digoxin | Digoxin | 79 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 71 | 22 |
| Warfarin Sodium | Warfarin Sodium | 51 | 14 |
| Corlanor | Ivabradine Hcl | 50 | 15 |
| Tacrolimus | Tacrolimus | 48 | 13 |
| Jardiance | Empagliflozin | 46 | 14 |
| Ranolazine Er | Ranolazine | 45 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 14 |
| Eplerenone | Eplerenone | 42 | 14 |
| Bumetanide | Bumetanide | 41 | 16 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 13 |
| Prednisone | Prednisone | 37 | 14 |
| Valsartan | Valsartan | 37 | suppressed |
| Gabapentin | Gabapentin | 36 | suppressed |
| Ramelteon | Ramelteon | 32 | suppressed |
| Sirolimus | Sirolimus | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 29 | suppressed |
| Lisinopril | Lisinopril | 29 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 11 |
| Verquvo | Vericiguat | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | 12 |
| Omeprazole | Omeprazole | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 13 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $496.84 · 9 records | Bard Peripheral Vascular, Inc. | OPSUMIT, Orenitram, PURIFIED CORTROPHIN GEL, Remodulin, UPTRAVI, Venovo, WINREVAIR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Merck Sharp & Dohme LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error